NCT05849467View on ClinicalTrials.gov

Central Nervous System Uptake of Anti-CD8+ T Cell Minibodies in Multiple Sclerosis and Progressive Multifocal Leukoencephalopathy

PHASE1RecruitingINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

October 19, 2023

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions
Multiple SclerosisProgressive Multifocal Leukoencephalopathy
Interventions
DRUG

89 Zr-Df-crefmirlimab

"an 80 kDa minibody (Mb) with high~affinity to CD8 glycoprotein (binding EC50 = 0.4 nM) that is conjugated with deferoxamine (Df)~and radiolabeled with the positron emitting radionuclide, Zr-89 (T1/2 78.4 hours)."

Trial Locations (1)

20892

RECRUITING

National Institutes of Health Clinical Center, Bethesda

All Listed Sponsors
lead

National Institute of Neurological Disorders and Stroke (NINDS)

NIH